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Abstract C-type natriuretic peptide (CNP) and brain natriu- 
retic peptide (BNP) are members of the natriuretic peptide fam- 
ily, which have been shown to interact with ANP-C/ANF-R2 
receptors in addition to ANP-B receptor subtypes. The present 
study was undertaken to investigate if the interaction of CNP and 
BNP with ANP-C receptors results in the inhibition of adenylyl 
cyclase activity. CNP and BNP inhibited adenylyl cyclase activ- 
ity in heart and brain striatai membranes in a concentration 
dependent manner with an apparent K~ between 0.1 and 1.0 nM. 
Maximal inhibition observed in heart membranes were about 25% 
and 35% for BNP and CNP respectively, however the inhibitions 
in brain striatal membranes were smaller (~20%). The inhibition 
was dependent on the presence of guanine nucleotides and was 
attenuated by pertussis toxin treatment. In addition, CNP inhib- 
ited the stimulatory effect of isoproterenol on adenylyl cyclase, 
whereas CNP as well as BNP showed an additive effect with the 
inhibitory response of angiotensin II on adenylyl cyclase activity. 
When the combined effect of C-ANF4_2~/BNP, C-ANF4_23/CNP 
and BNP/CNP at optimal concentrations was studied together on 
adenylyl cyclase activity, the percent inhibition remained the 
same for C-ANF4_23 and BNP or C-ANF4_23 and CNP, however, 
an additive inhibitory effect was observed for BNP and CNP. 
These results suggest hat CNP and BNP like C-ANF4_2s interact 
with ANP-C receptors and result in the inhibition of adenylyl 
cyclase activity. On the other hand, CNP and BNP interact with 
the ANP-C receptor, however, the interaction may be at different 
sites or there may be two subpopulations of ANP-C receptors 
specific for each of the peptides. These results indicate that BNP 
and CNP, like ANP and C-ANF4_23, inhibit the adenylyl cyclase/ 
cAMP signal transduction system through an inhibitory guanine 
nucleotide regulatory protein, by interacting with ANP-C recep- 
tor subtypes. 
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I. Introduction 
Atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP) and C-type natriuretic peptide (CNP) are a family of 
structurally related peptides containing a seventeen amino 
acid ring formed by a disulfide bridge. As compared to ANP, 
BNP has an additional six amino acid sequence in its amino 
*Corresponding author. Fax: (1) (514) 343 2111. 
Abbrev&tions: ANP, atrial natriuretic peptide (9%126); C-ANF 4 23, 
a ring-deleted analog of atrial natriuretic factor; C-ANF4 23 (des[ Gln~8, 
Ser 19, Gln 2°, Leu 21, GIy22]ANF4_23-NH2); CNP, C-type natriuretic pep- 
tide; BNP, brain natriuretic peptide; PT, pertussis toxin; G~, an inhib- 
itory guanine nucleotide regulatory protein; Gs, a stimulatory guanine 
nucleotide regulatory protein; GTPyS; guanosine 5'-0-(3-thio- 
triphosphate); All, angiotensin II. 
terminal extend [1,3,4] while CNP lacks the carboxy-terminal 
extend [2]. 
ANP has been reported to regulate a variety of physiological 
processes affecting cardiovascular homeostasis [5]. BNP also 
shares the same characteristics [2,3,6,7] but is less potent han 
ANP and has long lasting effects [8,9]. CNP, on the other hand 
is produced in the brain, anterior pituitary and cerebellum [6,10- 
12] and acts as a neurotransmitter to inhibit the same effects 
as those of ANP and BNP [13]. The concentration of CNP in 
brain is higher than the two other peptides [10]. CNP has also 
been shown to be secreted from cultured vascular smooth mus- 
cle cells [9], where it may function as growth inhibitor [14]. 
CNP influences muscular tone but has no natriuretic effect in 
mammals [15,16]. The diuresis and hypotension provoked by 
CNP are weaker than those of ANP and BNP [2]. 
ANP has been reported to stimulate guanylyl cyclase/cGMP 
and to inhibit the adenylyl cyclase/cAMP system in several 
tissues by interacting with their receptors [5]. By molecular 
cloning techniques, three subtypes of natriuretic peptide recep- 
tor (NPR) have been identified. These are NPR-A [17,18], 
NPR-B [19,20] and NPR-C [21]; NPR-A and NPR-B are mem- 
brane guanylyl cyclase, whereas NPR-C (clearance receptors) 
also known as ANF-R2 or ANP-C receptors have been shown 
to be coupled to adenylyl cyclase inhibition through the G~ 
regulatory protein [22,23] or to activation of phospholipase C 
[24]. NPR-A responds to stimulation by both ANP and BNP, 
however, ANP is more potent than BNP in stimulating ua- 
nylyl cyclase [17], however NPR-B is more responsive to BNP 
than ANP [19,20]. CNP on the other hand interacts with NPR- 
B with higher affinity and is probably its natural igand while 
BNP could interact with a NPR-B subtype or with another 
receptor [7,13,25]. 
The interaction of BNP and CNP with NPR-C has also been 
reported by receptor binding studies [14,21,26], however, it is 
not known whether this interaction results in the functional 
coupling to adenylyl cyclase/cAMP transduction system to 
which ANP-C receptors are coupled. We have therefore under- 
taken the present studies to examine if BNP and CNP, like 
ANP, could also inhibit adenylyl cyclase/cAMP system through 
Gi regulatory protein. 
2. Experimental 
2.1. Preparation of heart membranes 
The rat heart membranes were prepared in a similar manner as that 
of aorta-washed particles as described previously [22,23]. The heart 
ventricles were dissected out, and quickly frozen in liquid nitrogen and 
pulverized to a fine powder by using a mortar cooled in liquid nitrogen. 
The powder was homogenized by Teflon/Glass homogenizer ina buffer 
containing 10 mM Tris-HCl and 1 mM EDTA, pH 7.5, the homogenate 
was centrifuged at 1000 × g for 15 min at 4°C. The supernatant was 
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2.2. Preparation of brain striatal membranes and aorta washed particles 
The brain striatal membranes and aorta washed particles were pre- 
pared as described previously [23]. 
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2.3. Pertussis toxin-catalysed ADP-ribosylation 
The pertussis toxin (PT) treatment was performed as described previ- 
ously [22]. The heart membranes were incubated in a buffer containing 
25 mM glycylglycine (pH 7.5), 1 mM NAD +, 0,4 mM ATP, 0.4 mM 
GTP, 15 mM thymidine, 10 mM dithiothreitol, and ovalbumin (0.1 
mg/ml) without or with PT (5/.tg/ml) for 30 min at 30°C. The mem- 
branes were washed two to three times with 10mM Tris, 1 mM EDTA 
buffer, pH 7.5 and finally suspended in the same buffer and used for 
adenylyl cyclase activity determination. Pre-incubation of heart mem- 
branes at 30°C for 30 min in the absence or presence of PT resulted in 
a significant loss of enzyme activity (~40%) which was independ- 
ent of the presence of PT in the incubation medium. However the 
percent inhibition of adenylyl cyclase by CNP or BNP remained un- 
changed (data not shown). 
2.4. Adenylyl cyclase activity determination 
Adenylyl cyclase activity was determined by measuring cyclic [c~- 
32p]AMP formation from [c~-32p]ATP as described previously [22,23]. 
The typical assay medium contained 50 mM glycylglycine (pH 7.5), 0.5 
mM MgATE [c~-32P]PATP (1 1.5 × 106 CPM) 5 mM MgC12 (in excess 
of ATP concentration), 100 mM NaCI, 0.5 mM cAMP, 1 mM 3- 
isobutyl-l-methylxanthine, 0.1 mM EGTA, 10 pM GTPzS and an 
ATP-regenerating system consisting of 2 mM creatine phosphate, 0.1 
mg of creatine kinase/ml and 0.1 mg of myokinase/ml in a final volume 
of 200/.tl. Incubations were initiated with the addition of a reaction 
mixture to the membranes (30-70 pg), which had been thermically 
equilibrated for 2 min at 37°C. The reactions were conducted in tripl- 
icate at 37°C for 10 min and were terminated by the addition of 0.6 ml 
of 120 mM zinc acetate, cAMP was purified by co-precipitation f other 
nucleotides with ZnCO3 by the addition of 0.5 ml of 144 mM Na2CO3 
and subsequent chromatography using double column system de- 
scribed by Salomon et al. [27]. Under these assay conditions, adenylyl 
cyclase activity was linear with respect o protein concentration and 
time of incubation. The protein concentration was determined essen- 
tially as described by Lowry et al. [28] with crystalline bovine serum 
albumin as standard. 
2.5. Materials 
Male Sprague-Dawley rats (weight, 250 g) were provided by Charles 
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Fig. 1. Effect of various natriuretic peptides on adenylyl cyclase activity 
in rat heart membranes. Adenylyl cyclase activity was determined in the 
absence (basal, empty column) or presence of 0.1 BM ANP99_ 126 (black 
column), 0.1/~M BNP (hatched column), 0.1/IM CNP (finely hatched 
column) or 0.1 ,uM C-ANF4_:3 (cross-hatched column), as described in 
section 2. Values are the means +S.E.M. of three separate xperiments. 
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discarded and the pellet was suspended in 10 mM Tris-HCl/l mM 
EDTA. The membranes were washed two times and suspended finally 
in the 10 mM Tris-HCl and 1 mM EDTA pH 7.5 for adenylyl cyclase 
activity determination a d ADP-ribosylation studies. 
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Fig. 2. Effect of CNP and BNP on adenylyl cyclase activity in heart 
membranes (A) and brain striatal membranes (B). Adenylyl cyclase 
activity was determined as described in section 2 in the presence of 
various concentration of CNP (closed circles) or BNP (open circles). 
Values are the means + S.E.M. of three separate xperiments. The 
absolute nzyme activity in the presence of 10/.tM GTPyS in heart 
membranes was 677.3 + 12.9 pmol cAMP (mg protein × 10 min) -~ and 
brain striatal membranes was 839.7 _+ 70.8 pmol cAMP (mg protein × 5 
min) -~, respectively. 
River Canada inc. (St.-Constant, Quebec, Canada). ATP, cAME per- 
tussis toxin and isoproterenol were purchased from Sigma (St.-Louis, 
MO, USA). Creatine kinase (EC 2.7.3.2), myokinase (EC 2.7.4.3), GTP 
and guanosine 5'-[y-thio]triphosphate (GTPTS) were purchased from 
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Boehringer Mannheim (Montreal, Quebec, Canada). [ct-32p]ATP was 
from Amersham Corp. (Oakville, Ontario, Canada). BNP (32 amino 
acids) and CNP (22 amino acids) were obtained from Peninsula Lab. and 
Bachem (CA, USA), respectively. 
3. Results 
3.1. Effect of BNP and CNP on adenylyl o, clase activity 
In order to investigate if CNP and BNP interact with 
ANP-C receptors and result in the inhibition of adenylyl cyclase, 
the effect of these peptides were studied on adenylyl cyclase 
activity and were compared with the inihibitions elicited by 
ANP and C-ANF~23. The results shown in Fig. 1 indicate that 
ANP, C-ANF4_23, CNP and BNP at (0.1 pM) inhibited adenylyl 
cyclase activity to almost similar extent (between 30-40%) in 
heart membranes, indicating that BNP and CNP like ANP and 
C-ANF4_23 may also interact with adenylyl cyclase signal 
transduction system. Fig. 2 shows adenylyl cyclase inhibition 
by BNP and CNP at various concentrations in heart and brain 
striatal membranes. BNP and CNP both inhibited adenylyl 
cyclase activity in a concentration dependent manner in heart 
(A) and brain striatal (B) membranes with an apparent K~ be- 
tween 0.1 and 1 nM. The maximal inhibition observed in heart 
were about 35%, whereas about 20% inhibition was observed 
in brain striatum. Similar results were also observed in aorta 
(data not shown). 
3.2. Dependence of CNP inhibition of adenylyl cyclase on 
guanine nucleotides 
The inhibitory effect of ANP and C-ANF4_23 on adenylyl 
cyclase has been reported to be dependent on the presence of 
guanine nucleotides [22,23]. To examine if the inhibition elicited 
by the BNP and CNP is also dependent on the presence of 
guanine nucleotides, the effect of GTPyS was studied on the 
peptide-mediated inhibition of adenylyl cyclase activity. Table 
1 illustrates the effect of CNP on adenylyl cyclase from heart 
membranes in the absence and presence of various concentra- 
tions of GTPyS. CNP did not exert any effect on adenylyl 
cyclase activity in the absence of GTPyS; however, in the pres- 
ence GTPyS, CNP was able to inhibit the enzyme activity in 
a concentration-dependent manner. The maximal inhibition 
elicited by CNP (~25%) was at 1 /.tM GTPyS. Similar 
Table 1 
Dependence on guanine nucleotides ofinhibition of adenylyl cylcase by 
CNP in heart membranes 
Adenylyl cyclase activity 
pmol cAMP (mg protein × 10 
min) -1) 
GTPyS (M) -CNP +CNP Inhibition (%) 
None 109.0 + 2.0 103.0 + 0.8 5.5 + 2.5 
10 -9 143.9 + 2.7 123.8 + 0.1 14.0 + 1.7 
10 -8 389.0 + 2.9 330.8 + 7.3 15.0 + 2.5 
10 -7 761.8 + 4.2 618.8 + 13.8 18.8 + 2.3 
10 -6 953.2 + 13.9 732.6 + 1.5 23.1 + 1.3 
10 5 1042.1 + 29.5 824.4 + 18.7 20.9 + 4.0 
Adenylyl cyclase activity was determined in the presence of various 
concentrations of GTPyS alone or in combination with 0.1/.tM CNP 
as described in section 2. Values are the means + S.E.M. of three sepa- 
rate experiments done in triplicate. 
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Fig. 3. Effect of PT on BNP and CNP-mediated inhibition of adenylyl 
cyclase in rat heart membranes. Heart membranes were treated without 
(control) or with PT as described in section 2. Adenylyl cyclase activity 
was determined in the absence and presence of various concentrations 
of BNP (A) or CNP (B) in control (closed circle) and PT treated (open 
circle) membranes a described in section 2 in the presence of 10/tM 
GTPyS. Values are the means + S.E.M. of three separate experiments. 
The basal enzyme activities in control and PT-treated membranes were 
528.2 + 6.6 and 506.9 + 4.9 pmol cAMP (mg protein x I0 min) -1, 
respectively. 
results were also observed with BNP (data not shown). These 
results indicate that the receptors for BNP and CNP may also 
be coupled to adenylyl cyclase system through guanine nucleo- 
tide regulatory protein. 
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Fig. 4. Interaction of BNR CNP and C-ANF, 23 on adenylyl cyclase 
activity in rat aorta membranes. Adenylyl cyclase activity was deter- 
mined in the absence (Basal, open column) or presence of 0.1 tM 
C-ANE4 23 (C-ANF, cross-hatched column), 0.1 tM BNP (hatched 
column), 0.1 tM CNP (finely hatched column), alone or in combination 
with C-ANF 4 23 + BNP (dotted column), C-ANF4 23 + CNP (vertically 
hatched column) or BNP + CNP (black column) as described insection 
2. Values are the means _+ S.E.M. of three separate experiments. 
3.3. EfJect of pertussis toxin on BNP- and CNP-mediated 
inhibition of adenylyl cyclase 
Fig. 3 shows the effect of PT treatment on BNP- and CNP- 
mediated inhibition of adenylyl cyclase. BNP and CNP inhib- 
ited the enzyme activity in a concentration-dependent ma ner 
in control membranes, however, the inhibitions were com- 
pletely abolished by PT treatment. These data indicate that like 
ANP [22,23], the inhibitory effects of CNP and BNP on ade- 
nylyl cyclase are also mediated through Gi regulatory protein. 
3.4. Interaction of BNP, CNP and C-ANF 4 23 on adenylyl 
cyclase activity 
Since BNP and CNP, like ANP and C-ANF4 23, inhibited 
adenylyl cyclase activity through G i regulatory protein, it was 
of interest o examine if these peptides interact with the same 
ANP-C receptor population or interact with two distinctly dif- 
ferent receptor populations. Fig. 4 shows that C-ANF4_23, BNP 
and CNP inhibit adenylyl cyclase by 28, 15 and 29%, respec- 
tively, in aorta-washed particles, and when the effect of an 
optimal concentration f C-ANF 4 23 and BNP or C-ANF4_23 
and CNP was studied together on adenylyl cyclase, the percent 
inhibition remained the same. These data indicate that the BNP 
and CNP like C-ANF~23 elicit inhibition of adenylyl cyclase by 
interacting with the ANP-C receptor population. However, 
when the effect of an optimal concentration f CNP and BNP 
was studied together on adenylyl cyclase, almost additive inhib- 
itory effect was observed. These results indicate that CNP and 
BNP may be interacting with ANP-C receptors at distinctly 
different sites or there may be two subpopulations of ANP-C 
receptors pecific for each of the peptides and coupled to ade- 
nylyl cyclase/cAMP signal transduction system. 
3.5. Effect of CNP and BNP on stimulatory and inhibitory 
efJects of hormones on adenylyl cyclase activity 
The interaction of ANP with various stimulatory or inhib- 
itory hormones on adenylyl cyclase has been reported in vari- 
ous tissues [23,29,30]. Since CNP also inhibits adenylyl cyclase 
activity through G~ protein, it was of interest to examine ifCNP 
could also be able to interact with various agonists which stim- 
ulate or inhibit adenylyl cyclase through G~ and G~ proteins 
respectively. The results shown in Table 2 indicate that fl- 
adrenergic agonist isoproterenol stimulated adenylyl cyclase 
activity in heart membranes and CNP inhibited these stimula- 
tions. On the other hand, AII as reported previously [31] inhib- 
ited adenylyl cyclase activity by about 30% and CNP as well 
as BNP showed an additive ffect with the inhibitory response 
of AII. These data suggest that CNP or BNP and AII inhibit 
adenylyl cyclase by distinctly different mechanisms. A similar 
additive ffect of ANP and AII has been reported in glomeruli 
and aorta [29,32]. 
4. Discussion 
In the present studies, we demonstrate hat BNP and CNP, 
which have been reported to bind to the ANF-R2/ANP-C re- 
ceptor [14,21,26] inhibited adenylyl cyclase activity in a concen- 
tration dependent manner in heart as well as in brain striatal 
membranes, uggesting that the other signalling pathway 
through which these peptides mediate their physiological re- 
sponses may be adenylyl cyclase/cAMP signal transduction 
pathway to which ANP-C receptors are coupled [23,30]. A 
decrease in cAMP levels by BNP has recently been shown in 
rat vascular smooth muscle cells [33], however, these studies did 
not provide any mechanistic details of this effect. 
The inhibition of adenylyl cyclase by CNP and BNP like 
ANP or C-ANF4~23 was also dependent on the presence of 
guanine nucleotides and was attenuated by PT treatment and 
suggest hat CNP- and BNP-mediated inhibition of adenylyl 
cyclase requires the Gi regulatory protein as has been reported 
for the inhibition elicited by ANP or C-ANF,~23. 
ANP or C-ANF,_23 have been reported to interact with other 
hormone receptors which are coupled to adenylyl cyclase signal 
transduction system Gs or G~ proteins [29 31]. In the present 
studies, we have shown that CNP and BNP (data not shown) 
like ANP or C-ANF 4 23 [23,29,30] were also able to inhibit he 
Table 2 
Effect of natriuretic peptides on stimulatory and inhibitory responses 
of hormones on adenylyl cyclase activity 
Additions Adenylyl cyclase activity 
pmol (cAMP mg protein. 10 min) -* 
Experiment I 
None 145.3 + 24 
CNP (0.1 tM) 95.3 + 5 
Isoproterenol (50 tM) 425.9 + 1.5 
Isoproterenol + CNP 339.0 + 34.8 
Experiment 2 
None 251.05 _+ 8.2 
BNP (0.1 tM) 181.75 _+ 8.6 
CNP (0.1 tiM) 195.38 _+ 14 
All (10 tM) 176.94 + 10.65 
BNP + All 150.38 + 11.9 
CNP + All 159.0 + 16.6 
Adenylyl cyclase activity was determined in heart (Experiment 1)and 
aorta membranes (Experiment 2)in the presence of10 tM GTP or 10 
tM GTPyS respectively asdescribed in section 2. Values are means 
_+ S.E.M. of three separate experiments conducted in triplicate. 
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hormone-stimulated enzyme activity and showed additive ef- 
fect with inhibitory responses of All. These data suggest hat 
all the three peptides mediate adenylyl cyclase inhibition by the 
same or similar mechanism. This notion is further substantiated 
by our results on the combined effect of C-ANF4_23 and BNP 
or C-ANF4_23 and CNP, which resulted in the same extent of 
inhibition of adenylyl cyclase as that exerted by either of these 
peptides. These results strongly suggest hat C-ANF4_23, BNP 
and CNP use the same receptor ANP-C for inhibiting adenylyl 
cyclase/cAMP transduction system. The involvement of a com- 
mon neuromodulatory receptor ANP-C for C-ANF4_23, CNP 
and ANP in mediating the inhibition of purinergic and adrener- 
gic neurotransmission in isolated rabbit vas deference has re- 
cently been suggested [34]. 
Our results howing an additive inhibitory effect of CNP and 
BNP on adenylyl cyclase activity are intriguing and suggest that 
both these peptides may interact with ANP-C receptors at two 
different sites and inhibit adenylyl cyclase by distinctly different 
mechanism or alternatively, there may be two different subpop- 
ulations of ANP-C receptors for the interaction of CNP and 
BNP. The presence of ANP-C receptor subtype has also been 
shown in vascular tissue [35]. In addition, two different cDNAs 
encoding ANP-C receptor were identified in human umbical 
vein which differed only by deletion of 123 nucleotides in one 
of the transcripts [36]. A recent study by Koyama et al. [33] has 
shown that C-ANF4 23 and BNP but not CNP decreased cAMP 
levels in vascular smooth muscle cells which may suggest hat 
these cells may have a single population of ANP-C receptor 
subtype responsive to BNP and C-ANF4_23 and not to CNP. In 
addition Trachte et al. [37] by receptor binding studies also 
suggested the existence of ANP-C receptor subtypes in PC12 
cells. 
In conclusion, our results provide the first evidence that CNP 
and BNP interact with ANP-C receptors and elicit adenylyl 
cyclase inhibition through G i regulatory protein. It can be sug- 
gested that adenylyl cyclase/cAMP signal transduction system 
may be the other possible mechanism by which these natriuretic 
peptides elicit their physiological responses. 
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